About this trial
This project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hematopoietic cell transplantation (HCT) survivors and can be used to develop biologically informed interventions to improve quality of life and prolong the healthspan of individuals with accelerated aging.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 18 years and older who are competent to give their informed consent.
Ability to read, speak, and understand English.
Received a hematopoietic cell transplant within the previous 100 days.
Disqualifiers
Less then Aged 18 years and older who are competent to give their informed consent.
Cannot read, speak, and understand English.
Has not received a hematopoietic cell transplant within the previous 100 days.
Trial population
Patients undergoing HCT for hematologic cancers.
Trial design
Cohort
Prospective
Treatments tested in this trial
Biospecimen Collection
Procedure/SurgeryUndergo collection of blood sample
Electronic Health Record Review
Other interventionReview of medical records
Questionnaire Administration
Other interventionComplete questionnaires
Treatment groups
Trial outcomes
Primary outcomes
The number of participants with gene expression of cellular senescence marker p16.
This will be measured by mRNA/gene expression.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Medical College of Wisconsin
Lead sponsor
National Institute on Aging (NIA)
Collaborator